CA-SKYLOOM
6.9.2022 09:01:47 CEST | Business Wire | Press release
Skyloom and Space Compass (a newly formed joint venture between NTT and SKY Perfect JSAT) today announced that the companies signed a term sheet aimed to launch the first geostationary-based (GEO) data relay service over Asia that will leverage Skyloom’s cutting-edge communication and networking systems for the purpose of serving the rapidly growing Earth-Observation (EO) market for real-time, high-capacity, direct-to-cloud data transfer. The companies plan to deploy the first network infrastructure node over Asia in 2024 and anticipate expanding the GEO constellation to provide additional capacity and global coverage by 2026.
Global EO providers are rapidly expanding their constellations, thus creating immense amounts of data, typically in low-earth-orbit (LEO). The Compass-Skyloom system will provide an avenue for immediate, cost-effective transfer of EO data via GEO satellite direct to cloud so that their customers and end-users can leverage perishable information on a real-time basis. The system will rely on optical/laser communications terminals, enabling fibreless optical communications at the speed of business. The partnership combines the space heritage and operations experience of SKY Perfect JSAT, the telecommunications prowess of NTT, and the cutting-edge innovation of Skyloom to unveil both a joint architecture and service for the EO market.
"This new team, leveraging the state-of-the-art telecom technology and infrastructure solutions of Skyloom, will enable us to jointly deliver best-in-class service to our earth observation customers,” said Koichiro Matsufuji, Co-CEO, Space Compass.
“Skyloom is thrilled to be joining forces with Space Compass – which draws on the strengths of two market leaders in space operations and telecommunications. Together we look forward to providing groundbreaking data transport capabilities to the earth observation market, and this is only the beginning of what’s to come,” said Marcos Franceschini, Founder & CEO, Skyloom Global.
"By this partnership, we are excited to be able to provide ultra high-speed and real time data relay in a very economical manner for our customers as a first step toward a larger non-terrestrial network. We believe optical data relay technology is a keystone to innovate networking and computing in orbit between GEO, LEO and ground,” added Shigehiro Hori, Co-CEO, Space Compass.
About Space Compass Corporation
Space Compass is a joint venture company between NTT, Japanese ICT giant, and SKY Perfect JSAT Corporation, Asia’s largest satellite operator. We will launch a Space Integrated Computing Network to aid the realization of a sustainable society. For more information, visit our corporate website, space-compass.com.
About Skyloom Global Corporation
Skyloom is an Oakland, CA-based telecommunications innovator founded with the mission to develop, deploy, and operate one of the fundamental pieces of tomorrow's space communication infrastructure for the provision of data transport services on a planetary scale. They leverage deep heritage in space optical communications to enable real time data transfer so that customers and decisionmakers can leverage perishable information. www.skyloom.co
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220906005414/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Investor Supporting Japan’s Entertainment Industry, Yoshihiro Shimamura, to Visit France Workshop to be Held During the Cannes Film Festival28.4.2026 04:00:00 CEST | Press release
Shimamura Yoshihiro Film Planning Inc. (Head Office: Osaka, Japan; CEO: Yoshihiro Shimamura), a company engaged in film production and investment, will host a workshop in France during this year’s Cannes Film Festival, as part of its commitment to further advancing the entertainment industry. The company invests in leading entertainment-related businesses in Japan and places strong emphasis on long-term value creation. It identifies the cultural and entertainment sectors as high-growth areas and is actively involved in international co-productions as a core part of its film production activities. As a recent investment, the company acquired 2,000,000 shares of Hankyu Hanshin Holdings, Inc.—a major Japanese entertainment conglomerate known for producing content enjoyed across generations—and became a major shareholder (as of March 25, 2026). Through such investments, the company aims to support the global expansion of Japanese entertainment while exploring synergies with its own interna
Alsym Energy Announces Na-Series Battery Success Developed With Physics-Informed AI Platform27.4.2026 21:25:00 CEST | Press release
Alsym’s proprietary physics-informed AI platform powered the development of its Na-Series batteries—a non-flammable, high performance and low cost energy solution positioned to serve critical energy storage markets including data centers, utilities, telecommunications, commercial real estate, industrial and defense, among others. Alsym Energy, a pioneer in non-flammable, high-performance sodium-ion batteries, today announced details of the proprietary physics-informed AI platform used to develop the company’s recently launched Na-Series sodium-ion batteries. By integrating fundamental physics models with AI, autonomous testing and proprietary molecular diagnostics in a closed-loop system, Alsym is accelerating the design of safer, inexpensive, commercialized batteries through all phases of the development cycle. As global demand for electricity surges, the limitations of lithium-ion batteries have become increasingly apparent, particularly around safety and supply chain constraints. Li
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release
As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release
Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom